Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 
Pharmaceutical Executive Daily: White House Withdraws FDA Nomination For Dr. Heidi Overton’s
White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.
Nov 18
3 min
Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly
Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.
Nov 17
3 min
Pharmaceutical Executive Daily: FDA Approves Three New Therapies
FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.
Nov 16
3 min
The Ron Lanton Report: Ossium Health's Bone Marrow Bank
Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.
Nov 16
23 min
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Nov 13
1 min
Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.
Nov 12
2 min
Pharmaceutical Executive Daily: FDA Approves Pimjetmi
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Nov 11
2 min
Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.
Nov 10
2 min
Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Nov 9
2 min
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
Nov 6
2 min
Load more